AtriCure, Inc. ATRC
AtriCure, Inc. (Nasdaq: ATRC) is a cardio-renal-metabolic drug developer. Its lead program, BoxX-NoAF (Box Lesion and Left Atrial Appendage Exclusion Procedure), is marketed for Prevention of New Onset Atrial Fibrillation (Post-operative AF and Clinical AF). Its next catalyst on record is AtriClip FLEX-Mini 30mm: Commercial launch (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: AtriClip FLEX-Mini 30mm — Commercial launch (Q4 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| LeAAPS (Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction) | Prevention of ischemic stroke or systemic arterial embolism in cardiac surgery patients without pre-operative AF | device-combination | Approved |
| BoxX-NoAF | Prevention of post-operative AF and clinical AF | device-combination | Approved |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other approved cardio-renal-metabolic companies
- Artivion, Inc. AORT
- Amarin Corporation plc AMRN
- Scienture Holdings, Inc. SCNX
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.